Theriva Biologics, Inc. (AMEX:TOVX) stock is trading higher after the company announced it was selected as a finalist for Merck’s KGaA’s EMEA Advance Biotech Grant.

What To Know: Finalists for the grant will present their projects to a six-judge panel from Merck’s Emerging Biotech group at BIO Europe 2024 in Stockholm, Sweden.

Theriva, specifically General Director of EU Subsidiary Manel Cascalló, will provide an overview of VCN-01, which is currently undergoing a Phase 2b clinical trial for first-line metastatic pancreatic cancer in conjunction with standard chemotherapy. The presentation is scheduled for Nov. 4.

Winners receive financial support and guidance on navigating the path to commercialization, including consultation with M Ventures.

How To Buy Theriva Biologics Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Theriva Biologics's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

See Also: Intel Shares Surge In Premarket After Q3 Results: What’s Going On

TOVX Price Action: At the time of writing, Theriva shares are trading 31.6% higher at $1.92, according to data from Benzinga Pro.

Image: Unsplash/ Volodymyr Hryshchenko